REG - Angle PLC - Results of Eisai Phase 2 pilot study

AngleAnnouncement

21/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250321:nRSU5993Ba&default-theme=true

RNS Number : 5993B  Angle PLC  21 March 2025

 For immediate release  21 March 2025

 

 

ANGLE plc ("the Company")

 

UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF
EISAI CONTRACT

 

Development of both the prostate cancer androgen receptor assay and the
multi-cancer DDR micronuclei assay successfully completed for AstraZeneca

 

Results of Eisai Phase 2 pilot study supports the capability of the Parsortix
system for real-time assessment of breast cancer patient HER2 status and
applicability of Parsortix-based HER2 assay for use in ADC clinical trials

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell ("CTC") solutions for use in research, drug
development and clinical oncology, is delighted to announce that it has
successfully completed the AstraZeneca development work for both the
Parsortix-based Androgen Receptor ("AR") assay and the DNA damage response
("DDR") assay for the detection of micronuclei in CTCs as a measure of DNA
damage. ANGLE has also successfully completed its contract with the global
pharmaceutical company, Eisai Inc. ("Eisai") demonstrating the ability to
measure HER2 CTC status dynamically over time.

 

Update on AstraZeneca assay development projects

 

Both the developed assays (AR and DDR) have been approved for use by
AstraZeneca and we are currently using the assays to test blood samples from
patients. These developments put ANGLE in the position to be able to execute
large scale clinical trials for AstraZeneca. In addition, ANGLE is working to
progress discussions in other areas where we believe AstraZeneca could benefit
from adopting CTC analysis.

 

ANGLE will now add the AR and DDR micronuclei assays to its menu of validated
tests, which are available to pharma customers as a service from our clinical
laboratory. Both the AR and DDR markets are considerable and growing,
presenting an excellent opportunity for further pharma services contracts:

 

·    The AR therapeutic market is estimated to reach US$9.2 billion in
2033, driven by the rising prevalence of prostate cancer, the growing adoption
of targeted therapies, and the increasing demand for personalised medicine.
There are over 46,000 patients in 181 AR clinical studies, with ANGLE
targeting key players in the space.

 

·    The DDR therapeutic market was estimated at US$8.2 billion in 2024
and is forecast to grow to US$30.3 billion over the next decade. The complex
mechanisms involved in DNA repair and the potential for off-target effects
necessitate rigorous preclinical and clinical evaluations. As such, real-time
assessment of how the drug impacts the DDR pathway is particularly important
during clinical trials and is only made possible through liquid biopsy. There
are over 16,000 patients in 133 DDR clinical trials, again presenting a
significant opportunity for ANGLE, with the addition of the DDR micronuclei
assay complementing its γH2AX and pKAP1 DDR assays.

 

Results of Eisai Phase 2 pilot study

 

ANGLE provided CTC analysis with its Parsortix-based HER2 assay to assess
breast cancer patients' HER2 (human epidermal growth factor receptor 2) status
in a Phase 2 study of the HER2 targeting antibody-drug conjugate (HER2-ADC)
BB-1701. Detailed analysis of the results demonstrates that:

·    patient samples were successfully processed with consistent results
from two samples from each patient at each timepoint;

·    significant differences in HER2 CTC status and numbers of CTCs and
CTC clusters were observed between the results for two different timepoints
for the same patient before and after treatment.

 

This data is highly significant as it validates that ANGLE's HER2 assay is
capable of measuring changes in HER2 status over time, which is not possible
with a tissue biopsy as it is an invasive procedure which cannot always be
repeated. This information is key to utilising the assay in clinical studies
to assess patient treatment response and offers the potential to identify
patients likely to respond to HER2-ADCs.

 

The HER2 therapeutic market is a significant and growing sector, with a
reported value of US$9.4 billion in 2023, projected to reach US$13.2 billion
by 2030. The market is being driven by increasing usage of advanced and
targeted therapeutic options such as monoclonal antibodies and antibody-drug
conjugates (ADCs). Last year saw a record 481 new ADC trials announced, with
HER2 listed as the leading target candidate, thus highlighting the opportunity
for ANGLE's HER2 assay to support drug trials.

 

The full Phase 2 study of BB-1701 has not yet completed, and the drug efficacy
results are unknown.  However, Eisai have made the strategic decision not to
progress their option to BB-1701 further and have returned product development
rights to BlissBio. ANGLE has nevertheless developed a very good working
relationship with Eisai, who have indicated that there are other projects
where Parsortix-based CTC analysis may be relevant, and we hope to progress
these over time.

 

In addition, BlissBio, have confirmed their intention to progress BB-1701
themselves.  Accordingly, ANGLE is now seeking to engage with BlissBio in
order to work with them on the next stage of development of BB-1701 although
at this stage we have no specifics on this.

 

 

ANGLE Chief Executive Officer, Andrew Newland, commented:

"Successful completion of the AstraZeneca assay development projects is a key
milestone for the Company in progressing our aim for Parsortix-based CTC
analysis to be widely adopted for new and existing drugs to identify the right
drug for the right patient at the right time. There is a clear business case
for AstraZeneca and other large pharma to expand their markets for existing
drugs by identifying patients expressing the target biomarker on CTCs, as
biomarker status can change over time and impact response to treatment.

 

With regards to Eisai, we are delighted with the results of the HER2 CTC
analysis, in both its reproducibility and its ability to dynamically measure
HER2 changes over time, which we believe makes it ideally suited for HER2 and
HER2-ADC clinical trials. There is considerable evidence, including ANGLE's
in-house studies, that demonstrate that HER2 status of patients can change
over time, with HER2 positive CTCs being found in patients who were initially
HER2 negative based on their tissue biopsy.

 

Independent studies have shown that patients with HER2 positive CTCs can
benefit from treatment with HER2 targeted treatment. This could open larger
markets for HER2 drugs and improve outcomes for patients who would not
otherwise receive HER2 treatment."

 

 

 

For further information:

 

 ANGLE plc                                +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Corporate Broker)   +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin               +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                 +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESXBLLLEXLZBBB